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Abstract 
Varicella zoster virus (VZV) causes chicken pox as a primary infection following which it 
becomes latent in neurons. It may then reactivate to cause shingles (herpes zoster). Severity of 
lesions and VZV pathogenicity are depended on the host’s immune response and variant in VZV 
Dr Athina Myrto ChioniIdentification of VZV seroprevalance rate in general population may 
lead to develop new health strategic managements such as vaccination. Therefore, we aimed to 
provide a systematic review of the seroprevalence of VZV infection among Iranian population 
and estimate age- and gender- specific prevalence of VZV.   
Keywords “seroprevalence”, “varicella zoster virus”, and “Iran” were searched in international 
electronic databases and also in national Persian databases. Twenty two pooled studies among 
262 total studies containing (240 published articles, 18 dissertations, and 4 proceedings abstracts) 
from 1992 to 2014 with total sample size of 7867 individuals were included in the final review. 
Data was analyzed using random effect method. The heterogeneity was calculated using I-square 
statistics.  
The overall IgG seroprevalence rate of VZV infection in general population of Iran was 78.50% 
(95% CI; 77.74% - 79.25%). There was significant heterogeneity among the studies (P<0.0001; 
I²=99.4%). Furthermore, the relative risk of VZV infection is high in females (80.47%, 95% CI; 
79.40% - 81.54%) and older adults (95.30%, 95% CI; 94.11% - 96.48%).  
Our results may represent a true background and estimation of VZV infection in Iran and 
generate the cost-benefits immunization program. Moreover, the ensuing data suggests further 
attention on disease seroprevalence in order to obtain efficient data for therapeutic intervention 
targeted against VZV.  
Keywords: Varicella zoster virus, Seroprevalence, IgG, Immunity, Vaccination, Iran 
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Introduction: 
Varicella Zoster Virus (VZV) is a double-stranded DNA genome from alpha-herpes virus family. 
VZV is a persistent human pathogen causing chicken pox in the early stages of infection. VZV 
establish a latent infection within the spinal cord ganglia (dorsal root/sensory ganglia) during the 
primary infection that can be reactivated and cause herpes zoster (shingles) followed by 
secondary viremia (Arvin, 1996), (Gilden et al., 2011). Also clinical presentation of varicella is 
differed from chickenpox. In varicella, skin vesicles mostly distribute on the head but in 
chickenpox; vesicles, pustules, and scabs may be present at the same time on any part of skin 
(Gershon & Gershon, 2013).  Although VZV has host specificity and shows less DNA-sequence 
diversity, but few in vitro and in vivo reports demonstrated differences in pathogenic potential of 
VZV (Gershon & Gershon, 2013).       
The primary infection mostly manifested as macular rash, then formed papules and vesicular 
eruption, fever, while reactivation of dormant virus is involved in the severe form of the disease 
in adults (Mueller et al., 2008). Herpes zoster (HZ) is characterized by the painful blistering rash 
along the dermatomes (Sampathkumar et al., 2009). Although herpes zoster (HZ) is not limited 
to any age, the risk of HZ is increased by age and also with advanced immune-suppression 
(Liesegang, 2008). 
The incidence of this highly contagious infection increases markedly by the age (Yawn et al., 
2007). There are some potential consequences of VZV infection; serious complications such as 
skin lesions, pneumonia, encephalitis, and hepatitis that threaten adolescents (Arvin, 1996). This 
may lead to mortality in some cases (Arbeter, 1996). Moreover, pregnant women are another 
group infected by varicella with high risk of transmission to fetus and newborns (Paryani & 
Arvin, 1986). Embryos suffer from congenital varicella syndrome and congenital malformation 
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due to transplacental infection of maternal varicella (Shrim et al., 2012). Chorioretinitis, cerebral 
cortical atrophy, hydronephrosis, and cutaneous and bony leg defects, often presenting as a 
partial limb reduction are some examples of fetal deformations of varicella infection (Andrews, 
2004).  
Since different age groups of people are susceptible to HZ, the morbidity and mortality of zoster 
infection must be reduced by effective management and anti-viral therapy. Vaccination is one of 
the most appropriate protective ways used to increase immunity against varicella. As VZV 
vaccine is not a part of routine immunization schedule in Iran, data on the incidence of VZV are 
essential to schedule the effective vaccination programs. Seroprevalence studies can be counted 
as valuable approach to gain precise estimation of susceptible patients (Vandersmissen et al., 
2000). The most of the studies on prevalence rate of VZV infection in Iran have focused on high 
risk groups such as pregnant women, healthcare workers, and medical and paramedical students. 
On the other hand, there is no comprehensive information on the seroprevalence rate of VZV 
infection in overall population of Iran. To achieve this we employed a comprehensive systematic 
review on the seroprevalence of VZV and its risk factors association in general population in 
order to improve better health control policies. Here we highlight the necessity of vaccination 
program that may well lead to a faster resolution of VZV infection with obvious advantages for 
all VZV affected patients.  
 
Methods: 
Search strategy 
Databases such as PubMed, Web of knowledge, Scopus, Science Direct, Google Scholar, DOAJ, 
Embase, and national Persian databases (Magiran, Scientific Information Database [SID], Iran 
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Medex, and Iran Doc), as well as  conference proceedings were used to conduct comprehensive  
search of studies in the field of VZV infection. All studies from 1992 to 2014 were included 
using the search term of (Varicella zoster OR varicella zoster virus OR herpes zoster) AND 
(seroprevalence OR seroepidemiology OR epidemiological study OR immunity OR antibody) 
AND (Iran OR Islamic Republic of Iran).  
Study selection 
All cross sectional studies which aimed on IgG seroprevalence or seroepidemiology of VZV 
infection in the Iranian population were included. Of the total publications, duplicate and similar 
ones were identified and excluded. Since both English and Persian publications were included, 
publications with same data but different languages were removed in the next step. They were 
then reviewed by the two independent and blinded expert reviewers. The information was 
recorded on particularly designed sheets. Reviewers checked all potentially relevant studies and 
reached a consensus on all items. The evaluation was performed on the title and abstracts for the 
selection of studies. Any disagreement between the two reviewers was resolved after discussion 
and consultation with a third reviewer. Data were recorded on special designed forms containing 
general information about each article: author names, publication date, population size, regional 
target, age, and method of evaluation. The relevant studies were identified in to two stages: 1) all 
titles, abstracts and keywords were manually screened in order to find publications consistent 
with the main aim of the study; 2) full-text was downloaded and reviewed by the authors for 
further identification and confirmation of previous finding.  
 
Inclusion and exclusion Criteria for determine Eligible studies 
Inclusion criteria 
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The selection criteria included studies with all English and Persian articles that reported in the 
cross- sectional descriptive data from Iran with a focus on letters to the editors, abstracts, and 
dissertations studies on  the Seroprevalence/Seroepidemiology of VZV in Iran, The inclusion 
criteria  also concentrated on studies (a) with clear serological confirmation of IgG antibodies in 
sera of population using diagnostic methods (b) in high risk population group such as pregnant 
women and people of both genders and of all ages in every geographical region of Iran.  
 
Exclusion criteria 
We have excluded studies from Case reports, reviews, commentaries, author replies, animal 
studies, and non-accessible full-text articles. Insufficient raw data/ studies that have not been 
published in peer reviewed journals and studies with non-random sampling methods were also 
excluded.  
  
Data Extraction 
The data extraction form was used in order to provide a summary table containing necessary 
information of studies that were included in this review. Following data were extracted from 
each study: first author’s name, date of publication, location of study, characteristic of population 
(age range, sample size, and population groups), diagnostic method, prevalence of VZV and 
calculated odd ratio (OR) and p-value. The extracted data were then checked by all authors for 
further verification.  
Data Analysis 
Point estimates and their 95% confidence intervals (CI) of seroprevalence of the studies were 
calculated. An overall seroprevalence rate and subgroup analysis based on gender- and age-
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groups specific VZV seropositivity was calculated. A forest plot was used to visualize the 
heterogeneity among the studies. The heterogeneity was expected in advance, and statistical 
methods, I2 statistics (P<0.1) were used to quantify the variations. For the purpose of meta-
analysis, we assumed that the included studies were a random sample from a population of 
studies, and thus a random effects model was employed. Forest plots presented proportions of 
individual studies and overall seroprevalence. The meta-analysis was performed with the 
STATA software version 11.1 (StataCorp, College Station, TX, USA). 
 
Results 
Search Results 
The study selection proceeded as described in the flow chart in Fig. 1. A total number of 262 
publications were identified containing 240 databases-derived citations, 18 dissertations, and 4 
abstracts of congress proceedings. 154 out of 240 articles with duplicate content were removed. 
97 studies were considered for further screening following the exclusion of non-unique studies. 
The abstracts and full-text were then reviewed by the authors for screening irrelevant 
publications. Finally, 22 relevant reports with 7867 subjects were included in the systematic 
review and their information was summarized in Table 1. All eligible studies have used enzyme-
linked immunosorbent assay (ELISA) as a diagnostic method to detect anti-VZV IgG antibodies. 
 
Prevalence of VZV 
 22 articles reported VZV seroprevalence rate from 10 places among Iranian population; 9 
studies from Tehran (Akhbari, 2012;  Ehsanipour et al., 2009;  Pourakbari et al., 2012;  Sharifi & 
Emadi Ghanjin, 2005;  Talebi-Taher et al., 2013;  Talebi-Taher et al., 2014;  Talebi-Taher et al., 
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2010;  Talebi-Taher & Rezaie, 2012;  Vojgani et al., 2014), 2 studies from Babol (Bayani M, 
2013;  Bayani et al., 2013), 3 studies from shiraz (Moattari A, 2014;  Motamedifar M, 2006;  
Ziyaeyan et al., 2010), 1 study from Kashan (Taghavi Ardakani et al., 2013), 2 studies from 
Hamedan (Mamani M, 2009;  Mamani M, 2012), 1 study from Jahrom (Pourahmad et al., 2010), 
1 study from Kerman (Hosseininasab et al., 2013), 1 study from Kermanshah (Farshchi & 
Niayesh, 2011), 1 study from Bushehr (Barazesh et al., 2014), and 1 study from Qazvin (Allami 
et al., 2014). The Talebi-Taher et al, study in Tehran reported highest seroprevalence of VZV, 
with incidence rate of 97.9%  and the lowest VZV prevalence rate (15%) was found in Moattari 
et al (Moattari A, 2014). The results of heterogeneity test manifest extreme heterogeneity among 
reported studies (P=0.00; I²=99.4%). Due to severe heterogeneity, random effect meta-analysis 
was performed. The overall seroprevalence of VZ infection among the Iranian population using 
the random-effects model meta-analysis was 78.50% (95% CI; 77.74% - 79.25%). It is found 
that 5565 individuals out of 7867 were VZV IgG seropositive. Fig 2 is shown forest plot. We 
observed high heterogeneity between studies; hence only data from “general” populations 
(excluding high risk population such as pregnant women and haemodialysis patients) were used 
in meta-analysis. As shown in Fig. 3 the overall seroprevalence rate of VZV infection in the 
general population was 67% (95% CI; 65.83 - 68.18%).  
 
Subgroup analysis 
Classification of participants according to gender presented high seroprevalence of VZV among 
females (80.47% vs. 75.62%, P=0.001, respectively) (Fig. 4). In the next step, we analyzed 
seroprevalence rate of VZV based on age distribution. Interestingly, all studies were distributed 
into three age groups. The seroprevalence rate increased with age: from 46.21% (95% CI; 44.53-
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47.89%) in the age < 20 years to 88.97% (95% CI; 87.87-90.06%) in 20-40 years and then 
increased to 95.30% (95% CI; 94.11-96.48%) by age > 40 years. The peak prevalence was seen 
in the age >40 95.30% (95% CI; 94.11-96.48%) (Fig. 5).  
 
Discussion: 
In overall, VZV seropositivity rate is 78.50% in Iran. This is in consistent with studies from 
Turkish which reported 77.8% (Kanra et al., 2002) and 78% (Alp et al., 2005) VZV 
seropositivity increasing with age. Seroprevalence rate of VZV infection in Cyprus was reported 
84.1% in an age-related pattern (Kurugol et al., 2007). However, VZV prevalence was differed 
in other countries in Asia. In comparison to Iran, high VZV seroprevalence was reported from 
South Korea (92.7%) (Kang et al., 2008) and Israel (90.2%) (Cohen et al., 2006) while low VZV 
rate was reported from India (68.22%) (Lokeshwar et al., 2000), Singapore (55.3%) (Fatha et al., 
2014), Thailand (61.4%) (Migasena et al., 1997), and Pakistan (41.8%) (Akram et al., 2000). In 
all reports, an age-dependent pattern was demonstrated in VZV seropositivity.  
High seroprevalence of VZV IgG antibodies (94%) were found in adults in Amesterdam (95% 
CI; 92–96%) that is consistent with some European countries with more than 90% seropositivity 
(van Rijckevorsel et al., 2012). A Polish study with VZV seropositivity rate 76.6% (95% CI: 
74.6-78.7%) came to a same conclusion with Iranian’s rate of VZV prevalence (Siennicka et al., 
2009). Results from that study demonstrated a close relationship between seroprevalence and age 
but no correlation with gender, rural/urban areas and geographical regions of Poland (Siennicka 
et al., 2009).  
Moreover, we found a linear relationship between seropositivity and age. Age-specific VZV 
seroprevalence increased significantly from 46.21% for individuals aged less than 20 years to 
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95.30% for individuals aged more than 40 years (Fig. 5). Similar age-increasing results were 
systematically reported in North America, Europe, and Asia-Pacific- based studies (Kawai et al., 
2014). Age-dependent VZV seropositivty was also demonstrated in European population 
(Pinchinat et al., 2013). This systematic review also suggests that women have slightly high rates 
of VZV susceptibility than men (80.47% vs. 75.62%, P=0.001, respectively). 
 There is now revealed that women have an increased risk of developing varicella zoster. As the 
study population is unequally distributed on gender, high numbers of infected-women may lead 
to false seropositivity rates for women. While there are different results in seroprevalence level 
in different countries, even among neighboring countries, most studies were in agreements with 
age-related patterns of seroprevalence. Therefore, this finding provides a strong impetus to spur 
further research in an important global health imperative involving patients with VZV infection 
and emphasizes to focus on immunization programs capable of protecting elderly populations 
against VZV pathogenesis.  
Findings from this systematic review revealed significant heterogeneity even after focus on 
stratification of study population on general population without consideration high risk people 
(Fig. 3). Variation in seroprevalence of varicella infection may depend on different risk factors. 
It is shown that risk factors such as age, gender, ethnicity, genetic susceptibility, exogenous 
boosting of immunity from varicella contacts, underlying cell-mediated immune disorders, 
mechanical trauma, psychological stress, and immunotoxin exposure could modulate the 
incidence of varicella (Thomas & Hall, 2004). There are other reasons to clarify heterogenic 
prevalence results. The prevalence of VZV may be affected by climatic factors (Kang et al., 
2011). It was found that Asian countries with temperate climates make a favor condition for 
varicella virus transmission (Lee, 1998). Temperate climates in Sri Lanka participate in high 
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VZV seroprevalence rates (Liyanage et al., 2007). It was observed that VZV seroprevalence rate 
among young adults in temperate locations of Brazil was noticeably higher than that of  the 
tropical regions (Reis et al., 2003). High rates of VZV seropositivity in childhood in temperate 
climates and in adults in hot and tropical regions were reported in some studies (Schmid & 
Jumaan, 2010;  Sengupta & Breuer, 2009). In addition to the influence of climatic differences in 
the incidence of VZV infection, seasonal pattern was also reported in the seroprevalence of VZV 
in temperate regions. On the other hand, its prevalence is higher in winter and spring (Rice, 
2011). The rate of VZV seroprevalence is high, 90%, in North of Iran as a temperate region. This 
might be due to the fact that Northern region-derived studies focused on high-risk populations 
(pregnant women and healthcare workers), therefore high rates of seroprevalence was expected. 
This would have provided more useful information if seasonal pattern was also considered in 
these studies. In order to explore the effect of geographical region on this issue, more 
investigations are required in Northern provinces and other provinces of Iran with different 
climates. Comprehensive epidemiological data on general population in different regions is 
required to achieve further information on VZV prevalence. Fig. 6 demonstrates many 
unanalyzed regions and/or same regions with multiple results that should be further analyzed. 
Further research is needed to achieve more precisely and reliable results and facilitate the 
comparison of data from different region. 
Differences in seroprevalence between natives and immigrants such as Afghan, may determine 
the effects of climate factors on the seroprevalence. Of the other possible explanation for 
heterogeneity could be the individuals participating in the study, as few investigations quoted in 
this analysis were based on vulnerable people such as pregnant women and/or healthcare 
workers with a great heterogeneity  (Bayani M, 2013;  Bayani et al., 2013).  
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Insufficient number of studies on VZV seroprevalence restricted comprehensive searching, 
which is a problem in any systematic review. Therefore, we had to use all different studies and 
populations, thereby finding wide heterogeneity. Furthermore, there were some limitations in 
pooled publications. First, different populations in view of size, their occupation, location of 
birth and geographical state, age, and gender were surveyed in study design. Second, low number 
of populations restricted random sampling. Third, although same method was used in these 
studies; however, different types of kits might have influenced the sensitivity and specificity of 
results. Last, there are many unreported regions and also some places with more than one report 
in Iran (Fig. 6). Despite all limitations, significant heterogeneity was not unexpected.  
Collectively, VZV is associated with establishment of two diseases following primary infection 
(chickenpox) and reactivation of latent infection (shingles). It may associate with pulmonary, 
neurologic, and cutaneous complications (Gnann, 2002). Since wide range of neurological 
manifestations such as aseptic meningitis, myelitis, peripheral motor neuropathy, encephalitis, 
Gullain-Barr syndrome, and stroke syndromes may occur in patients at any age, they are 
considered as the most important complications. Patients treated with immunosuppressive drugs 
due to cancer, HIV, transplants, and diabetes are more susceptible to be affected by HZ (Albrecht 
M, 2011). Moreover, VZV infection in pregnancy puts the expectant mothers at high risk for 
mortality and morbidity. Their pregnancy might lead to congenital varicella syndrome with 
destructive effects on fetus and newborns (Gardella & Brown, 2007). The airborne transmittance 
route of VZV made it as a highly contagious human disease (Schmid & Jumaan, 2010) and 
reactivation of latent virus may also affect people. Therefore, it needs more attention for cost-
effective treatment and preventive strategies.  
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Obviously, accurate understanding of the epidemiology of disease is the perquisite step for 
obtaining effective health control program that could attenuate the destructive effect of 
disease/infection on human health. Varicella vaccination not only can reduce the rate and 
incidence of VZV but also decreases its severity (Schmid & Jumaan, 2010). It is renowned that 
varicella deaths are now preventable by vaccines (Meyer et al., 2000). For example, a significant 
reduction in varicella deaths in US was observed after successful implementation of 1- dose 
vaccination program. The most severe outcomes of disease could be eliminated following the 2-
dose program (Marin et al., 2011). “The epidemiology of VZV has important implications for 
future vaccine strategies” (Kudesia et al., 2002). Comprehensive population-based studies 
provide valuable data to planning immunization programs and evaluate the effect of vaccination 
as a cost-effective program (Brisson et al., 2001). Serologic studies provide detailed information 
about varicella immunity and varicella-relating factors.  
The present study was performed based on the importance of VZV specific antibody assay to 
evaluate immunity levels against the disease. The serologic data from 22 articles studying 
different ages, provinces, and at risk groups in Iran were collected. Although the most accurate 
results are dependent on participation of all geographical regions, systematic analysis of the 
current information may lead to effective monitoring in other regions. 
 
Conclusion  
Consequently our results demonstrated high VZV seroprevalence in Iran especially in North of 
Iran. Direct relationship has been found between age and prevalence of VZV. Our results show 
that women are more susceptible to varicella infection than men. Because of insufficient data 
from different climates, we cannot exactly direct a relationship between seroprevalence and 
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climate. Therefore, more screening and appropriate programs on disease prevention, treatment, 
and management planning are needed for virus eradication and reducing the social and economic 
burden of varicella infection in societies. Further investigations considering seroprevalence 
analysis, may provide a common condition for comparing prevalence rate and prioritizing 
treatment methods.  
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Figures  
 
 
 
Figure 1: Flow diagram of selection strategies and including articles 
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Figure 2: Forest plot diagram of 22 studies showing IgG seropositivity rates of Varicella Zoster 
infection in Iranian population (first author and year of publication) 
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Figure 3: Forest plot diagram of 10 studies containing general populations showing IgG 
seropositivity rates of Varicella Zoster infection in Iranian population (first author and year of 
publication) 
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Figure 4: Forest plots of VZV seroprevalence in the males (A) and females population (B).  
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Figure 5: Forest plots of VZV seroprevalence in different age groups: (A) ˂ 20; (B) 20-40; (C) 
˃40 
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Figure 6: The seropositivity rate of varicella zoster infection in different regions of Iran. 
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Tables 
Table 1: Characteristics of included studies  
Reference  Study 
dates 
Study 
region 
Total 
individua
ls  
Seroprevalence 
(%) 
IgG positive 
(n) 
Age range 
(Year) 
Study 
population 
Method  
Akhbari et al. 
(Akhbari, 2012) 
2012 Tehran 42 83.3 35 17-29 Medical students ELISA 
Vojgani et al. 
(Vojgani et al., 
2014) 
2011-
2012 
Tehran 267 13 35 ≤ 7 Healthy children ELISA 
Talebi-Taher et 
al. (2010) 
(Talebi-Taher et 
al., 2010) 
2009 Tehran 405 71.4 289  19 - 50 Healthcare 
workers 
EIA 
Talebi-Taher & 
Rezaie (2012) 
(Talebi-Taher & 
Rezaie, 2012) 
2009 Tehran  400 78.25 313  20 - 40  Inpatients ELISA 
Talebi-Taher et 
al. (2013) 
(Talebi-Taher et 
al., 2013) 
2010 Tehran 187 97.9 183  18 - 88  Hemodialysis 
patients 
EIA 
Talebi-Taher et 
al. (2014) 
(Talebi-Taher et 
al., 2014) 
2010 Tehran  400 90.3 361  16 - 43  Pregnant women EIA 
Sharifi & Emadi 
(2005) (Sharifi & 
Emadi Ghanjin, 
2005) 
2003-
2005 
Tehran  635 83.6 531  1 - 60  Health volunteers ELISA 
Pourakbari et al. 
(2012) 
(Pourakbari et al., 
2012) 
2008 Tehran 412 65.3 269  10 - 25 Children, adults, 
and medical 
students 
ELISA 
 
 
28 
 
Ehsanipour et al. 
(2009)(Ehsanipou
r et al., 2009) 
2009 Tehran 120 42.5 51  1 - 16  Children  EIA 
Bayani et al. 
(2013) 
2010-
2011 
Babol, 
Mazandaran 
427 90.2 385  16 - 50  
 
Pregnant women ELISA 
Bayani et al. 
(2013) 
2011-
2012 
Babol, 
Mazandaran 
459 94.6 434  20 - ˃40 Healthcare 
workers 
ELISA 
Motamedifar et 
al. 
(2006)(Motamedi
far M, 2006) 
2002-
2003 
Shiraz  270 35.2 95  6-10  Young children  ELISA 
Ziyaeyan et al. 
(2010) (Ziyaeyan 
et al., 2010) 
2008 Shiraz, 
southern Iran 
843 66.3 559  1-70  Outpatients ELISA 
Moattari et al. 
(2014)(Moattari 
A, 2014) 
2014 Shiraz 180 15 27  18- 21 Medical and 
dental students 
ELISA 
Ardakani et al. 
(2013) (Taghavi 
Ardakani et al., 
2013) 
2011 Kashan  558 27.6 154  1-15 Primary health 
services 
ELISA 
Mamani et al. 
(2009)(Mamani 
M, 2009) 
2009 Hamedan 250 84.4 211  32 ± 9.6* Healthcare 
workers 
ELISA 
Mamani et al. 
(2012)(Mamani 
M, 2012) 
2009-
2010 
Hamedan 270 78.4 210  24 - ≥34 Pregnant women ELISA 
Pourahmad et al. 
(2010) 
(Pourahmad et 
al., 2010) 
2006-
2008 
Jahrom 
(south of 
Iran) 
334 72.7 242  12 – 45  Young women  ELISA 
Hosseininasab et 
al. 
(2013)(Hosseinin
asab et al., 2013) 
2013 Kerman, 
southern Iran 
723 89.35 646  24.1 ± 6.3* Women on 
reproductive age 
ELISA 
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Farshchi & 
Niyaesh (2011) 
(Farshchi & 
Niayesh, 2011) 
2012 Kermanshah 188 
 
62 
84.5 
84.5 
159  
52  
23-40 
 
18-25 
Healthcare 
workers 
 
Students  
ELISA 
Barazesh et al. 
(2014)(Barazesh 
et al., 2014) 
2009-
2010 
Bushehr 180 74.5 134  17-24  Female students ELISA 
Allami et al. 
(2014) (Allami et 
al., 2014) 
2012 Qazvin   255 74.5 190  18-49   Medical, nursing, 
and obstetrics 
students  
ELISA 
* Mean age ± SD of these studies was accessible.  
 
